BIOSTAR PHARM-B (02563)
| Auditor | From | To | Release Date / Document Links | Reason for Change |
|---|---|---|---|---|
| Wuyige/Daxin | 25-Aug-25 | |||
| Daxin | 23-May-25 | 25-Aug-25 | The Company will change its accounting standards from HKFRS Accounting Standards to China Accounting Standards for Business Enterprises (CASBE) starting from the financial year of 2025. Daxin has confirmed that, except for the unresolved matter in relation to the qualified opinion about the existence, rights and obligations, completeness, accuracy and valuation of the underlying assets, including the Fund Investments, and liabilities of the Fund there are no other matters in connection with its retirement that need to be brought to the attention of the shareholders. | |
| Kpmg | 23-Oct-24 | 24-Apr-25 | Could not reach a consensus on the audit fee and timetable for the completion of the remainder of the audit of consolidated financial statements of the Company and its subsidiaries for the year ended 31 December 2024. KPMG were not able to reasonably estimate the time and cost required to complete the audit due to the company has not provided all of the information and documents required in relation to supporting documents, interviews and confirmations in connection with the Three Investments valued at US$5m. |